2023
HIV risk profile and prevention needs of individuals seeking monkeypox (mpox) vaccination in an urban clinic in the U.S.: a brief report
Ogbuagu O, Sharma M, Igiraneza G, Andrews L, Tuan J, Barakat L. HIV risk profile and prevention needs of individuals seeking monkeypox (mpox) vaccination in an urban clinic in the U.S.: a brief report. BMC Infectious Diseases 2023, 23: 146. PMID: 36890468, PMCID: PMC9993362, DOI: 10.1186/s12879-023-08075-5.Peer-Reviewed Original ResearchMeSH KeywordsAdultCross-Sectional StudiesHIV InfectionsHomosexuality, MaleHumansMaleMonkeypoxPre-Exposure ProphylaxisSmallpox VaccineConceptsHIV risk profilesSTI riskPre-exposure prophylaxis useRisk profileMedian age 28 yearsHIV-negative respondentsHIV-negative participantsHIV-negative individualsReceptive anal intercourseModerate alcohol useAge 28 yearsCross-sectional surveySexual partner numberProphylaxis useResultsEighty-onePrEP knowledgeHIV positivityPrevention gapUrban clinicCenter clinicPrevention needsSTI historyInclusion criteriaAnal intercourseIllicit substances
2022
Proactive strategies to optimize engagement of Black, Hispanic/Latinx, transgender, and nonbinary individuals in a trial of a novel agent for HIV pre-exposure prophylaxis (PrEP)
Cespedes M, Das M, Hojilla JC, Blumenthal J, Mounzer K, Ramgopal M, Hodge T, Torres TS, Peterson C, Shibase S, Elliott A, Demidont AC, Callaghan L, Watson CC, Carter C, Kintu A, Baeten JM, Ogbuagu O. Proactive strategies to optimize engagement of Black, Hispanic/Latinx, transgender, and nonbinary individuals in a trial of a novel agent for HIV pre-exposure prophylaxis (PrEP). PLOS ONE 2022, 17: e0267780. PMID: 35657826, PMCID: PMC9165827, DOI: 10.1371/journal.pone.0267780.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAnti-HIV AgentsFemaleHispanic or LatinoHIV InfectionsHomosexuality, MaleHumansMalePre-Exposure ProphylaxisSexual and Gender MinoritiesTransgender PersonsConceptsClinical trialsHIV incidencePre-exposure prophylaxis clinical trialHispanic/LatinxRecruitment goalsGood participatory practice guidelinesOngoing phase 3 trialsHIV pre-exposure prophylaxisTransgender womenTransgender menPhase 3 trialPre-exposure prophylaxisCommunity-based clinicsFuture clinical trialsClinical trial numberEvidence-informed recommendationsLatinx MSMGender nonbinary individualsCisgender MSMNovel agentsPractice guidelinesStudy populationBlack MSMUS sitesTrials
2021
Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial
Ogbuagu O, Ruane PJ, Podzamczer D, Salazar LC, Henry K, Asmuth DM, Wohl D, Gilson R, Shao Y, Ebrahimi R, Cox S, Kintu A, Carter C, Das M, Baeten JM, Brainard DM, Whitlock G, Brunetta JM, Kronborg G, Spinner CD, team D, Antinori A, Apea V, Asmuth D, Avery A, Benson P, Bergin C, Berhe M, Brar I, Brinson C, Brunetta J, Burack J, Campbell T, Cespedes M, Clarke A, Coleman M, Coll J, Casal M, Creticos C, Crofoot G, Cruickshank F, Cua E, Daar E, de Wet J, DeJesus E, Del Romero Guerrero J, Dinges W, Doblecki-Lewis S, Donovan T, Dosekun O, Flamm J, Gallant J, Gerstoft J, Gilson R, Gladstein J, Grant R, Grossberg R, Haas B, Halperin J, Hardy W, Hare C, Hassler S, Hengel R, Henry W, Hodge T, Hosek S, Hurt C, Iandiorio M, Jessen H, Kegg S, Knecht G, Kronborg G, Krznaric I, LaMarca A, Larsen C, Larsen O, Lazzarin A, Leen C, Lucasti C, Mallon P, Mannheimer S, Markowitz M, Martorell C, Mayer K, Mills A, Molina J, Morris S, Mounzer K, Nwokolo N, Ogbuagu O, Osiyemi O, Petroll A, Philibert P, Phoenix J, Pialoux G, Podzamczer D, Post F, Prins M, Ramgopal M, Rashbaum B, Reeves I, Richmond G, Rieger A, Ruane P, Salazar L, Scarsella A, Schembri G, Scott M, Shalit P, Sinclair G, Sobieszczyk M, Spinner C, Stephens J, Szabo J, Taylor S, Thompson M, Tremblay C, Trottier B, Voskuhl G, Wade B, Wohl D, Workowski K, Yawetz S, Young B. Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet HIV 2021, 8: e397-e407. PMID: 34197772, DOI: 10.1016/s2352-3018(21)00071-0.Peer-Reviewed Original ResearchConceptsTenofovir disoproxil fumaratePre-exposure prophylaxisTenofovir alafenamideDisoproxil fumarateBone mineral densityHIV infectionPlacebo tabletsMineral densityHIV preventionHIV-1 pre-exposure prophylaxisTransgender womenAdult cisgender menNon-inferior efficacyWeek 96 resultsPrimary efficacy outcomeCisgender menPhase 3 trialIncident HIV infectionHIV-1 infectionNon-inferiority trialLong-term safetyMore weight gainRenal safety biomarkersSelf-reported sexual behaviorStudy medication
2018
Perceptions of HIV transmission and pre-exposure prophylaxis among health care workers and community members in Rwanda
Kambutse I, Igiraneza G, Ogbuagu O. Perceptions of HIV transmission and pre-exposure prophylaxis among health care workers and community members in Rwanda. PLOS ONE 2018, 13: e0207650. PMID: 30475841, PMCID: PMC6261021, DOI: 10.1371/journal.pone.0207650.Peer-Reviewed Original ResearchConceptsKigali University Teaching HospitalPre-exposure prophylaxisNew HIV infectionsHealth care workersHIV infectionHIV transmissionHealth facilitiesCare workersUniversity Teaching HospitalService delivery barriersMultiple community sitesSafer sex practicesPrEP implementationHIV testingHealthcare workersSmoking cigarettesTeaching hospitalMosquito bitesPrevention servicesHIVNew infectionsHealthcare providersHealthcare professionalsPrEPSex practicesPrevalence and Correlates of Unhealthy Alcohol and Drug Use Among Men Who Have Sex with Men Prescribed HIV Pre-exposure Prophylaxis in Real-World Clinical Settings
Ogbuagu O, Marshall BDL, Tiberio P, Ogunbajo A, Barakat L, Montgomery M, Almonte A, Wray T, Williams EC, Edelman EJ, Chan PA. Prevalence and Correlates of Unhealthy Alcohol and Drug Use Among Men Who Have Sex with Men Prescribed HIV Pre-exposure Prophylaxis in Real-World Clinical Settings. AIDS And Behavior 2018, 23: 190-200. PMID: 30145707, PMCID: PMC7020905, DOI: 10.1007/s10461-018-2260-9.Peer-Reviewed Original ResearchConceptsUnhealthy alcohol useUnhealthy alcoholPre-exposure prophylaxisUnhealthy substance useDrug useHIV acquisitionAlcohol useSubstance useHIV pre-exposure prophylaxisReal-world clinical settingProspective observational studyHIV-positive partnerHIV risk behaviorsStructured clinical assessmentFrequent drug usePrEP outcomesPrEP useRisk factorsClinical assessmentObservational studyPositive partnerReal-world settingMultivariate analysisYounger ageSexual partnersHIV Risk perception and eligibility for pre-exposure prophylaxis in women involved in the criminal justice system
Rutledge R, Madden L, Ogbuagu O, Meyer JP. HIV Risk perception and eligibility for pre-exposure prophylaxis in women involved in the criminal justice system. AIDS Care 2018, 30: 1282-1289. PMID: 29527934, PMCID: PMC6085161, DOI: 10.1080/09540121.2018.1447079.Peer-Reviewed Original ResearchConceptsPrEP implementation programsPre-exposure prophylaxisHIV risk behaviorsPrEP awarenessHIV pre-exposure prophylaxisRisk behaviorsPersonal HIV riskPrEP care continuumPrEP-eligible womenHepatitis C infectionPrimary care providersHIV risk perceptionUnsafe injection practicesMeeting eligibility criteriaPrison/jailCross-sectional surveyRecent transactional sexLifetime substance usePrEP eligibleC infectionEligible womenCare continuumHIV riskCare providersHigh risk
2017
Condomless sex and HIV transmission among serodifferent couples: current evidence and recommendations
Koff A, Goldberg C, Ogbuagu O. Condomless sex and HIV transmission among serodifferent couples: current evidence and recommendations. Annals Of Medicine 2017, 49: 534-544. PMID: 28409656, DOI: 10.1080/07853890.2017.1320423.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAnti-HIV AgentsCondomsFemaleHIV InfectionsHIV SeropositivityHumansMalePre-Exposure ProphylaxisSexual PartnersUnsafe SexConceptsHIV transmissionSerodifferent couplesAntiretroviral therapyCondomless sexCondom useHIV-positive sexual partnerHuman immunodeficiency virus (HIV) infectionImmunodeficiency virus infectionPre-exposure prophylaxisHIV transmission riskUse of condomsInfected partnerHIV infectionHIV incidenceSexual transmissionHIV preventionPreventive benefitsVirus infectionCurrent evidencePrevention strategiesSexual partnersTransmission riskIndividual riskSexInfection